PRGO: Future Upside Will Hinge On Infant Nutrition Turnaround

Analysts have trimmed the Perrigo price target to $16.50 from $17. This reflects updated views on modest revenue growth potential, slightly lower profit margins, and a higher assumed future P/E multiple, while keeping the discount rate essentially unchanged.

Analyst Commentary

Recent Street research shows a mixed but informative view of Perrigo, with both supportive and cautious voices reacting to recent results and business trends. The updated $16.50 target sits within this range of views and reflects how analysts are weighing execution in core categories against ongoing pressure in infant nutrition.

Bullish Takeaways

Bullish analysts point to management comments that Perrigo ended 4Q25 and FY25 with share gains in private label store brands and key branded products, which they view as helpful for defending revenue assumptions at the updated $16.50 target.
Distribution, contract, and share gains in the broader business are seen as signs that execution in core categories remains intact. This gives some confidence that current margin and growth expectations can be met if this trend holds.
Supportive research emphasizes that, outside infant nutrition, the business is described as performing well. This is factored into models that assume Perrigo can sustain its competitive position in store brand and branded self-care products.
Some bullish analysts maintain positive ratings even after trimming targets. They indicate that they still see the current valuation as reasonable relative to their expectations for the underlying franchise, excluding the more challenged pieces.

Bearish Takeaways

Bearish analysts at JPMorgan and others have lowered price targets to levels such as $15 and cite enough uncertainty around execution and profitability to justify a more cautious stance on valuation.
The infant nutrition business is repeatedly flagged as a pressure point, with the last two years described as challenging. This feeds into more conservative assumptions on both revenue and margin resilience.
Softness in infant nutrition is seen as limiting the benefit from share gains elsewhere, leading bearish analysts to question how quickly the company can translate operational wins into higher earnings power.
Target cuts from prior levels such as $20 and $18 down to $17 and $15 signal concern about the balance between modest growth expectations and the risk that profitability could fall short of earlier forecasts.

What's in the News

Perrigo recorded goodwill impairment charges of $330.8 million for the quarter ended March 28, 2026, compared with $1.2 million a year earlier, which directly affects reported earnings for that period (Key Developments).
The company reaffirmed fiscal 2026 earnings guidance, with total net sales growth outlook of 5.5% to 1.5% decline versus the prior year, signaling management’s current expectations for the year (Key Developments).
The U.S. International Trade Commission opened an investigation involving Perrigo and other respondents over certain over the counter topical lidocaine patches related to alleged patent infringement, which could lead to exclusion or cease and desist orders depending on the outcome (Key Developments).
Perrigo completed a share repurchase program covering 3,400,000 shares, or 2.49% of the company, for a total of $164.24 million under the buyback announced on November 8, 2018, with no additional shares repurchased across the three most recent reported tranches (Key Developments).
A media blog highlighted a rumor related to Perrigo, which has added an extra layer of speculation around the stock, although details remain limited at this stage (Periodicals).

Valuation Changes

Fair Value: The $17.00 fair value estimate has been reduced slightly to $16.50.
Discount Rate: The discount rate has edged down from 9.30% to about 9.29%, a very small change that leaves the overall risk assumption broadly similar.
Revenue Growth: The revenue growth assumption has shifted from a 0.38% decline to a 0.03% increase, indicating a move from slightly contracting sales to essentially flat to marginally positive growth.
Net Profit Margin: The profit margin assumption has been trimmed from 1.97% to 1.75%, reflecting a modest reduction in expected profitability.
Future P/E: The assumed future P/E multiple has risen from 36.9x to 40.8x, which implies a higher valuation being applied to the same stream of earnings.

8 views

Key Takeaways

Strong consumer shift toward store-brand OTC and structural industry tailwinds are driving sustainable revenue growth and stable demand for Perrigo's core product segments.
Portfolio simplification and operational efficiency initiatives are enhancing profitability, supporting innovation investment, and accelerating the company's financial deleveraging.
Weak demand, fierce competition, low pricing power, and operational challenges threaten Perrigo's ability to grow revenue, protect margins, and sustain long-term market share.

Catalysts

About Perrigo

Provides over-the-counter health and wellness solutions in the United States, Europe, and internationally.What are the underlying business or industry changes driving this perspective?

Increasing consumer cost-consciousness is driving stronger adoption of store-brand (private label) OTC products, with Perrigo reporting accelerated unit and volume share gains; this structural shift is expanding Perrigo's addressable market and supports enduring top-line revenue growth.
The aging global population and rising consumer interest in self-care and wellness continue to create longer-term demand tailwinds for Perrigo's OTC and nutrition products, providing stable, defensive revenue streams even in periods of macro uncertainty.
Recent new business wins in US store-brand OTC have outpaced distribution losses for the first time since the 2024 reset, with net new contract gains expected to add $75M+ to sales in the second half-directly supporting a step-change in revenue growth and operating income.
Strategic portfolio simplification, including the recent sale of the Dermacosmetics business, allows Perrigo to focus investment on core, higher-growth segments, bolstering gross and operating margins and accelerating deleveraging.
Ongoing operational initiatives like Project Energize and supply chain reinvention are generating $150M–$200M in savings, funding innovation and margin-accretive investments, which are expected to further improve gross margins and net earnings over time.

Perrigo Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

Analysts are assuming Perrigo's revenue will remain fairly flat over the next 3 years.
Analysts assume that profit margins will increase from -42.9% today to 1.8% in 3 years time.
Analysts expect earnings to reach $73.4 million (and earnings per share of $0.52) by about May 2029, up from -$1.8 billion today.
In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 41.1x on those 2029 earnings, up from -0.9x today. This future PE is greater than the current PE for the US Pharmaceuticals industry at 16.1x.
Analysts expect the number of shares outstanding to grow by 0.45% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 9.29%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

Ongoing soft category consumption in key markets, including declining total category consumption in the U.S. and decelerating consumption in the EU, could indicate underlying secular weakness in demand for OTC and self-care products, which would limit Perrigo's ability to drive sustained top line (revenue) growth over the long term.
Increasing competitive intensity in the infant formula and OTC markets-with heavy promotion, new product launches from competitors, and non-optimal shelf placement-suggests that Perrigo may struggle to maintain or grow market share, potentially constraining both revenue and net margins.
The company's dependence on volume-driven, private label and store brand products-with historically limited pricing power-makes it vulnerable to cost inflation (e.g., raw materials, tariffs) that could compress gross and net margins if cost offsets and price increases are not fully realized.
Product quality and supply chain challenges, such as the recent isolated infant formula production scrap event, introduce risk of variable production costs, lost sales, and potential reputational damage, all of which could negatively impact margins and future earnings if recurring or if quality issues arise.
Slower-than-expected recovery and ramp-up in key businesses (notably infant formula) and headwinds from possible continued importation of foreign products (e.g., European organic formula) highlight structural industry risks and regulatory uncertainties, possibly constraining both Perrigo's market share and long-term revenue/earnings growth.

Valuation

How have all the factors above been brought together to estimate a fair value?

The analysts have a consensus price target of $16.5 for Perrigo based on their expectations of its future earnings growth, profit margins and other risk factors.
However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $20.0, and the most bearish reporting a price target of just $14.0.
In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $4.2 billion, earnings will come to $73.4 million, and it would be trading on a PE ratio of 41.1x, assuming you use a discount rate of 9.3%.
Given the current share price of $11.72, the analyst price target of $16.5 is 29.0% higher.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on Perrigo?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

PRGO: Profit Margins And Operational Strength Will Support Long-Term Upside Potential